The BCL-2 Inhibitor Venetoclax Augments Immune Effector Function Mediated by Fas Ligand, TRAIL, and Perforin/Granzyme B, Resulting in Reduced Plasma Viremia and Decreased HIV Reservoir Size during Acute HIV Infection in a Humanized Mouse Model-Reference-Cited by-同舟云学术

The BCL-2 Inhibitor Venetoclax Augments Immune Effector Function Mediated by Fas Ligand, TRAIL, and Perforin/Granzyme B, Resulting in Reduced Plasma Viremia and Decreased HIV Reservoir Size during Acute HIV Infection in a Humanized Mouse Model

Published:2022-12-21 Issue:24 Volume:96 Page:
ISSN:0022-538X
Container-title:Journal of Virology
language:en
Short-container-title:J Virol

Author:

Chandrasekar Aswath P.¹^ORCID,Cummins Nathan W.¹^ORCID,Natesampillai Sekar¹,Misra Anisha¹^ORCID,Alto Alecia¹^ORCID,Laird Greg²^ORCID,Badley Andrew D.¹³

Affiliation:

1. Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota, USA

2. Accelevir Diagnostics, Baltimore, Maryland, USA

3. Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, USA

Abstract

This study is the first to examine the applicability of BCL-2 inhibition in the setting of active HIV infectionin vivo. Furthermore, this study demonstrates that venetoclax significantly enhances target cell killing induced by Fas ligand, TRAIL, and perforin/granzyme B and synergistically enhances autologous NK and CD8 cells’ killing of target cells.

Funder

HHS | NIH | National Institute of Allergy and Infectious Diseases

amfAR, The Foundation for AIDS Research

Publisher

American Society for Microbiology

Subject

Virology,Insect Science,Immunology,Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/jvi.01730-22

Reference81 articles.

1. HIV DNA Set Point is Rapidly Established in Acute HIV Infection and Dramatically Reduced by Early ART

2. HIV elite control is associated with reduced TRAILshort expression